# Emp-Activity: Empagliflozin Functional Capacity

> **NCT05350202** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 3431 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** Empagliflozin

## Key facts

- **NCT ID:** NCT05350202
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-18
- **Primary completion:** 2024-07-25
- **Final completion:** 2024-07-25
- **Target enrollment:** 3431 (ACTUAL)
- **Last updated:** 2025-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05350202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05350202, "Emp-Activity: Empagliflozin Functional Capacity". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05350202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*